Relevance of lipopolysaccharide levels in HIV-associated neurocognitive impairment: the Neuradapt study
- 225 Downloads
Contributory factors to HIV-associated neurocognitive disorders (HAND) have been shown to include age, co-morbid infections, medication toxicity, virological, genetic and vascular mechanisms, as well as microbial translocation of lipopolysaccharide (LPS), which is suspected to trigger monocyte activation and increase trafficking of infected cells into the brain. In this study, our aim was to assess the degree of neurocognitive impairment in a group of randomly selected HIV-infected patients and investigate potential risk factors, including LPS plasma levels. Furthermore, we evaluated the relevance of LPS as a potential marker for screening patients with mild neurocognitive impairment. LPS plasma levels were compared among patients with HAND and those with no HAND. As LPS has also been shown to be elevated in hepatitis C co-infection, the analysis was stratified according to the presence or not of hepatitis C virus (HCV) co-infection. Differences between groups were evaluated using chi-square tests and Kruskal–Wallis non-parametric tests. Stepwise logistic regression was performed to identify independent risk factors for HAND in the subgroups of HCV-positive and negative patients. A p value <0.05 was considered significant. Analyses were conducted using SPSS® software. From December 2007 to July 2009, 179 patients were tested (mean age 44, 73 % male, 87 % on treatment, 30 % HCV co-infected, median CD4 504/ml and 67 % with viral load below 40 copies/ml). HAND was identified in 40/179 patients (22 %), the majority displaying asymptomatic neurocognitive impairment or mild neurocognitive disorder. Univariate analysis showed that age, illicit drug use, hepatitis C co-infection, prior AIDS-defining events, CD4/CD8 ratio and LPS plasma levels were significantly associated with HAND. The median LPS level was 98.2 pg/ml in the non-HAND group versus 116.1 pg/ml in the HAND group (p < 0.014). No differences were found in LPS values between subgroups of impairment. There was a clear association between LPS levels and HAND in the HCV-positive group (p = 0.036), while there was none in the HCV-negative group (p = 0.502). No difference in degree of hepatic fibrosis was found between the HAND and non-HAND groups. In conclusion, LPS levels were associated with HAND in the HCV-positive group, while, in the HCV-negative group, age and pro-viral DNA were the only variables independently associated with HAND. There was no difference in degree of liver disease as predicted by score of fibrosis between HAND and non-HAND groups. The role of HCV co-infection and higher LPS levels in the pathogenesis of HAND in patients with viral suppression on treatment requires further investigation.
KeywordsLipopolysaccharide HIV-associated neurocognitive disorders Antiretroviral therapy
We wish to thank the patients who accepted to take part in the Neuradapt study. Dr Eric Fontas provided helpful advice on the statistical analysis.
We also wish to thanks Patrizia Comi.
Study funding: This study received funding from Abbott, Glaxo-Smith-Kline, Boehringer, Gilead, Tibotec and Merck companies. The pharmaceutical companies mentioned above did not participate in the design or the conduct of the study, in the collection, management, analysis and interpretation of data or in the preparation, review or approval of the manuscript. All the phases of the work described above were prepared independently by the authors.
- Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69:1789–1799PubMedCrossRefGoogle Scholar
- Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, Kazzaz Z, Bornstein E, Lambotte O, Altmann D, Blazar BR, Rodriguez B, Teixeira-Johnson L, Landay A, Martin JN, Hecht FM, Picker LJ, Lederman MM, Deeks SG, Douek DC (2006) Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 12:1365–1371PubMedCrossRefGoogle Scholar
- Chattergoon M, Levine J, Cox A. HIV and HCV stimulate production of the inflammatory cytokine IL-18 through activation of the Nalp 3 inflammasome in monocytes. J Immunol 2012Google Scholar
- French AL, Evans CT, Agniel DM, Cohen MH, Peters M, Landay AL, Desai SN. Microbial translocation and liver disease progression in HIV/Hepatitis C co-infected women. J Infect Dis. 2013. [Epub ahead of print]Google Scholar
- Goodkin K, Shapshak P et al (2009) The spectrum of Neuro-AIDS disorders: pathophysiology, diagnosis and treatment. ASM press, Washington DCGoogle Scholar
- Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I (2010) Charter group. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: Charter study. Neurology 75:2087–2096PubMedCrossRefGoogle Scholar
- Kushner LE, Wendelboe AM, Lazzeroni LC, CharY A, Winters MA, Osinusi A, Kottilil S, Polis MA, Holodnyi M. Immune biomarker differences and changes comparing HCV mono-infected, HIV/HCV co-infected and HCV spontaneously cleared patients. Plos one 2012Google Scholar
- Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, Gelman BB, McArthur JC, McCutchan JA, Morgello S, Simpson D, Grant I, Ellis RJ, CHARTER Group (2008) Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 65:65–70PubMedCrossRefGoogle Scholar
- Marchetti G, Nasta P, Bai F, Gatti F, Bellistrì GM, Tincati C, Borghi F, Carosi G, Puoti M (2012) Monforte Ad. Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients. PLoS One 7(2):e32028PubMedCrossRefGoogle Scholar
- Mc Arthur JC, Steiner J, Sacktor N, Nath A (2010) Human immunodeficiency virus associated neurocognitive disorders: mind the gap. Ann Neurol 67:699–714Google Scholar
- Papasavvas E, Pistilli M, Reynolds G, Bucki R, Azzoni L, Chehimi J, Janmey PA, DiNubile MJ, Ondercin J, Kostman JR, Mounzer KC, Montaner LJ (2009) Delayed loss of control of plasma lipopolysaccharide levels after therapy interruption in chronically HIV-1-infected patients. AIDS 28:369–375CrossRefGoogle Scholar
- Shiramizu B, Ananworanich J, Chalermchai T et al (2012) Failure to clear intra-monocyte HIV infection linked to persistent neuropsychological testing impairment after first-line combined antiretroviral therapy. Failure to clear intra-monocyte HIV infection linked to persistent neuropsychological testing impairment after first-line combined antiretroviral therapy. J Neurovirol 18(1):69–73PubMedCrossRefGoogle Scholar